ORG Partners LLC Has $1.35 Million Holdings in Pfizer Inc. (NYSE:PFE)

ORG Partners LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 6.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,879 shares of the biopharmaceutical company’s stock after buying an additional 2,967 shares during the period. ORG Partners LLC’s holdings in Pfizer were worth $1,351,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Strategic Financial Concepts LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at approximately $38,000. Quest Partners LLC acquired a new position in shares of Pfizer during the 2nd quarter worth $570,000. Angeles Wealth Management LLC grew its position in Pfizer by 24.0% in the second quarter. Angeles Wealth Management LLC now owns 11,580 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 2,239 shares during the last quarter. AGF Management Ltd. increased its position in Pfizer by 6.7% during the 2nd quarter. AGF Management Ltd. now owns 1,223,841 shares of the biopharmaceutical company’s stock worth $34,243,000 after purchasing an additional 76,464 shares in the last quarter. Finally, HHM Wealth Advisors LLC increased its holdings in shares of Pfizer by 9.3% during the second quarter. HHM Wealth Advisors LLC now owns 6,311 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 538 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of several recent research reports. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim decreased their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Citigroup started coverage on shares of Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Trading Down 0.2 %

Shares of PFE stock traded down $0.06 during trading hours on Friday, hitting $26.80. 9,599,357 shares of the company were exchanged, compared to its average volume of 31,494,996. The company has a 50 day simple moving average of $26.21 and a two-hundred day simple moving average of $28.05. The firm has a market cap of $151.88 billion, a P/E ratio of 36.22, a P/E/G ratio of 0.63 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.17) earnings per share. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.42%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is presently 232.43%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.